900 related articles for article (PubMed ID: 8837542)
1. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women.
Josse RG
CMAJ; 1996 Oct; 155(7):929-34. PubMed ID: 8837542
[TBL] [Abstract][Full Text] [Related]
2. Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada.
CMAJ; 1996 Oct; 155(8):1113-33. PubMed ID: 8873639
[TBL] [Abstract][Full Text] [Related]
3. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis.
Hodsman A; Adachi J; Olszynski W
CMAJ; 1996 Oct; 155(7):945-8. PubMed ID: 8837544
[TBL] [Abstract][Full Text] [Related]
4. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 4. Calcium nutrition and osteoporosis.
Murray TM
CMAJ; 1996 Oct; 155(7):935-9. PubMed ID: 8837543
[TBL] [Abstract][Full Text] [Related]
5. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 7. Fluoride therapy for osteoporosis.
Murray TM; Ste-Marie LG
CMAJ; 1996 Oct; 155(7):949-54. PubMed ID: 8837545
[TBL] [Abstract][Full Text] [Related]
6. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 8. Vitamin D metabolites and analogs in the treatment of osteoporosis.
Jones G; Hogan DB; Yendt E; Hanley DA
CMAJ; 1996 Oct; 155(7):955-61. PubMed ID: 8837546
[TBL] [Abstract][Full Text] [Related]
7. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 9. Calcitonin in the treatment of osteoporosis.
Siminoski K; Josse RG
CMAJ; 1996 Oct; 155(7):962-5. PubMed ID: 8837547
[TBL] [Abstract][Full Text] [Related]
8. Comparative cardiovascular effects of different progestins in menopause.
Rosano GM; Fini M
Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
[TBL] [Abstract][Full Text] [Related]
9. Osteoporosis: new hope for the future.
Masi L; Bilezikian JP
Int J Fertil Womens Med; 1997; 42(4):245-54. PubMed ID: 9309458
[TBL] [Abstract][Full Text] [Related]
10. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
Burger H
Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
[TBL] [Abstract][Full Text] [Related]
11. Postmenopausal hormone therapy: cardiovascular risks.
Prescrire Int; 2003 Apr; 12(64):65-9. PubMed ID: 12674130
[TBL] [Abstract][Full Text] [Related]
12. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
13. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
15. Osteoporosis and cardiovascular disease: benefit-risk of hormone replacement therapy.
Sammartino A; Cirillo D; Mandato VD; Di Carlo C; Nappi C
J Endocrinol Invest; 2005; 28(10 Suppl):80-4. PubMed ID: 16550729
[TBL] [Abstract][Full Text] [Related]
16. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration.
Stefanick ML
Am J Med; 2005 Dec; 118 Suppl 12B():64-73. PubMed ID: 16414329
[TBL] [Abstract][Full Text] [Related]
17. HRT dosing regimens: continuous versus cyclic-pros and cons.
Shoupe D
Int J Fertil Womens Med; 2001; 46(1):7-15. PubMed ID: 11294619
[TBL] [Abstract][Full Text] [Related]
18. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2006; 13(3):340-67; quiz 368-9. PubMed ID: 16735931
[TBL] [Abstract][Full Text] [Related]
19. Contraception for the perimenopausal patient.
Upton GV
Obstet Gynecol Clin North Am; 1987 Mar; 14(1):207-27. PubMed ID: 3306520
[TBL] [Abstract][Full Text] [Related]
20. Use of low-dosage 17 beta-estradiol for the prevention of osteoporosis.
Ettinger B
Clin Ther; 1993; 15(6):950-62; discussion 949. PubMed ID: 8111815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
